Clinical Cancer Research CR Balducci Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gery, S.
Right arrow Articles by Koeffler, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gery, S.
Right arrow Articles by Koeffler, H. P.
Clinical Cancer Research Vol. 11, 3184-3190, May 1, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Down-Regulation and Growth Inhibitory Role of C/EBP{alpha} in Breast Cancer

Sigal Gery1, Sakae Tanosaki1, Shikha Bose1, Namrata Bose1, Jay Vadgama2 and H. Phillip Koeffler1

Authors' Affiliations: 1 Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California at Los Angeles School of Medicine and 2 Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California

Requests for reprints: Sigal Gery, Cedars-Sinai Medical Center, Davis Building 5066, 8700 Beverly Boulevard, Los Angeles, CA 90048. Phone: 310-423-4609; Fax: 310-423-0225; E-mail: gerys{at}cshs.org.

Purpose: CCAAT/enhancer binding proteins (C/EBP) are a family of transcription factors that regulate proliferation and differentiation in a variety of tissues. The purpose of this study was to explore the possibility that C/EBP{alpha} is involved in breast cancer.

Experimental Design: We quantified C/EBP{alpha} mRNA expression levels in 24 primary breast tumors, 16 normal breast samples, and 8 breast cancer cell lines using quantitative real-time reverse transcription-PCR assay. C/EBP{alpha} protein levels were further determined by immunohistochemical analysis. To examine the consequence of C/EPB{alpha} expression in breast cancer, we stably transfected an inducible C/EPB{alpha} expression vector into three breast cancer cell lines.

Results: Low expression of C/EBP{alpha} mRNA was found in 83% of primary breast cancer samples. Immunohistochemical study further showed either a markedly reduced or undetectable expression of C/EBP{alpha} protein in 30% of breast cancer specimens. The other 70% of breast cancers had C/EBP{alpha} expression in both the cytoplasm and nucleus; in control, C/EBP{alpha} was localized to the nucleus in the normal ductal cells. C/EBP{alpha} expression was associated with estrogen- and progesterone receptor–negative status. Induction of C/EBP{alpha} expression in these cell lines resulted in growth inhibition accompanied by G0-G1 cell cycle arrest and reduced anchorage-independent cell growth. C/EBP{alpha} expression was associated with down-regulation of c-myc and up-regulation of p21, PPAR{gamma}, and the breast epithelial differentiation marker, maspin.

Conclusions: These results suggest that reduced expression of C/EBP{alpha} may play a role in the development and/or progression of breast cancer.

Key Words: C/EBP{alpha} • antiproliferative • breast cancer




This article has been cited by other articles:


Home page
Anticancer ResHome page
R. SEIFEDDINE, M.-C. FULCHIGNONI-LATAUD, and L. MASSAAD-MASSADE
Down-regulation of C/EBP{alpha} in Breast Cancer Cells by Hypoxia-Estrogen Combination is Mainly Due to Hypoxia
Anticancer Res, April 1, 2009; 29(4): 1227 - 1231.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Dhawan, R. Weider, and S. Christakos
CCAAT Enhancer-binding Protein {alpha} Is a Molecular Target of 1,25-Dihydroxyvitamin D3 in MCF-7 Breast Cancer Cells
J. Biol. Chem., January 30, 2009; 284(5): 3086 - 3095.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Seifeddine, A. Dreiem, E. Blanc, M.-C. Fulchignoni-Lataud, M.-A. L. F. Belda, F. Lecuru, T. H. Mayi, N. Mazure, V. Favaudon, C. Massaad, et al.
Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-{alpha} Expression in Breast Cancer Cells
Cancer Res., April 1, 2008; 68(7): 2158 - 2165.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Fritah, C. Saucier, O. De Wever, M. Bracke, I. Bieche, R. Lidereau, C. Gespach, S. Drouot, G. Redeuilh, and M. Sabbah
Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells
Mol. Cell. Biol., February 1, 2008; 28(3): 1114 - 1123.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. Yang, Y. Jiang, S.F. Wu, M.Y. Zhou, Y.L. Wu, and G.Q. Chen
CCAAT/enhancer-binding protein {alpha} antagonizes transcriptional activity of hypoxia-inducible factor 1 {alpha} with direct protein-protein interaction
Carcinogenesis, February 1, 2008; 29(2): 291 - 298.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Cheng, D. V. Yu, J.-H. Zhou, and D. J. Shapiro
Tamoxifen Induction of CCAAT Enhancer-binding Protein {alpha} Is Required for Tamoxifen-induced Apoptosis
J. Biol. Chem., October 19, 2007; 282(42): 30535 - 30543.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. D. Loomis, S. Zhu, K. Yoon, P. F. Johnson, and R. C. Smart
Genetic Ablation of CCAAT/Enhancer Binding Protein {alpha} in Epidermis Reveals Its Role in Suppression of Epithelial Tumorigenesis
Cancer Res., July 15, 2007; 67(14): 6768 - 6776.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Wolf, J. O'Kelly, T. Rubinek, M. Tong, A. Nguyen, B. T. Lin, H.-H. Tai, B. Y. Karlan, and H. P. Koeffler
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Cancer Res., August 1, 2006; 66(15): 7818 - 7823.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. S. Basseres, E. Levantini, H. Ji, S. Monti, S. Elf, T. Dayaram, M. Fenyus, O. Kocher, T. Golub, K.-k. Wong, et al.
Respiratory Failure Due to Differentiation Arrest and Expansion of Alveolar Cells following Lung-Specific Loss of the Transcription Factor C/EBP{alpha} in Mice
Mol. Cell. Biol., February 1, 2006; 26(3): 1109 - 1123.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Gery, A. F. Gombart, W. S. Yi, C. Koeffler, W.-K. Hofmann, and H. P. Koeffler
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia
Blood, October 15, 2005; 106(8): 2827 - 2836.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.